Abstract:figure legend In rodents experiencing ischaemic (I/R) acute kidney injury, a 10 day regimen of resveratrol (RSV) post‐injury ameliorated multiple aspects of maladaptive repair, including tubular injury, cellular death, mitochondrial dysfunction, disrupted antioxidant response, inflammatory processes and the initiation of fibrotic pathways. These beneficial effects led to a reduction in the progression towards chronic kidney disease (CKD), evident even 5 months post‐injury. Created with Biorender.com. Acute kidney injury (AKI) often triggers physiological processes aimed at restoring renal function and architecture. However, this response can become maladaptive, leading to nephron loss and fibrosis. Although the therapeutic effects of resveratrol (RSV) are well established, its impact after AKI and for subsequent chronic kidney disease (CKD) remains unclear. This study assessed whether transient administration of RSV following ischaemia–reperfusion injury (IRI) could prevent the progression to CKD. Forty‐one male Wistar rats were assigned randomly to sham surgery, bilateral renal ischaemia for 30 min (IR) or IR+RSV. The RSV treatment commenced 24 h after IRI and continued for 10 days. The rats were studied for either 10 days or 5 months, after which kidney function and structure were evaluated. Mitochondrial homeostasis, oxidant defence and renal inflammation state were also evaluated. Despite having the same severity of AKI, rats receiving RSV for 10 days after IRI exhibited significant improvement in kidney histological injury and reduced inflammation, although renal haemodynamic recovery was less pronounced. Resveratrol effectively prevented the elevation of tubular injury‐related molecules and profibrotic signalling with reduced myofibroblast proliferation. Furthermore, RSV substantially improved the antioxidant response and mitochondrial homeostasis. After 5 months, RSV prevented the transition to CKD, as evidenced by the prevention of progressive proteinuria, renal dysfunction and tubulointerstitial fibrosis. This study demonstrates that a brief treatment with RSV following IRI is enough to prevent maladaptive repair and the development of CKD. Our findings highlight the importance of the early days of reperfusion, indicating that maladaptive responses can be reduced effectively following severe AKI. Key points Physiological processes activated after acute kidney injury (AKI) can lead to maladaptive responses, causing nephron loss and fibrosis. Prophylactic renoprotection with resveratrol (RSV) has been described in experimental AKI, but its impact after AKI and for subsequent chronic kidney disease (CKD) remains unclear. In this study, we found that histological tubular injury persists 10 days after ischaemia–reperfusion injury and contributes to a failed repair phenotype in proximal tubular cells. Short‐term RSV intervention influenced the post‐ischaemic repair response and accelerated tubular recovery by reducing oxidative stress and mitochondrial damage. Furthermore, RSV targeted inflammation and profibrotic signalling during the maladaptive response, normalizing both processes. Resveratrol effectively prevented AKI‐to‐CKD transition even 5 months after the intervention. The study serves as a proof of concept, proposing RSV as a valuable candidate for further translational clinical studies to mitigate AKI‐to‐CKD transition.

Resveratrol Exerts Dose‐response Anti‐fibrotic and Pro‐fibrotic Effect in Renal Tubular Epithelial Cells

Resveratrol Exerts Dose-Dependent Anti-Fibrotic or Pro-Fibrotic Effects in Kidneys: A Potential Risk to Individuals with Impaired Kidney Function

Resveratrol Alleviates Hepatic Fibrosis in Associated with Decreased Endoplasmic Reticulum Stress-Mediated Apoptosis and Inflammation

Resveratrol Suppresses the Myofibroblastic Phenotype and Fibrosis Formation in Kidneys Via Proliferation‐related Signalling Pathways

Resveratrol Inhibits Epithelial-Mesenchymal Transition and Renal Fibrosis by Antagonizing the Hedgehog Signaling Pathway

The anti-inflammatory activity of resveratrol in acute kidney injury: a systematic review and meta‐analysis of animal studies

Resveratrol reinforces the therapeutic effect of mesenchymal stem cell (MSC)-derived exosomes against renal ischemia‒reperfusion injury (RIRI)-associated fibrosis by suppressing TGF-β-induced epithelial-mesenchymal transition

Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction

Resveratrol Ameliorates Early Diabetic Nephropathy Associated with Suppression of Augmented TGF-β/smad and ERK1/2 Signaling in Streptozotocin-Induced Diabetic Rats.

Resveratrol Mitigates Uremic Toxin-Induced Intestinal Barrier Dysfunction in Chronic Kidney Disease by Promoting Mitophagy and Inhibiting Apoptosis Pathways

Renal Denervation Significantly Attenuates Cardiorenal Fibrosis in Rats with Sustained Pressure Overload.

Resveratrol Alleviates Inflammatory Responses and Oxidative Stress in Rat Kidney Ischemia-Reperfusion Injury and H2O2-Induced NRK-52E Cells via the Nrf2/TLR4/NF-κB Pathway

Effects of Resveratrol on Renal Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis

Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases

Resveratrol ameliorates diabetic nephropathy in rats through negative regulation of the p38 MAPK/TGF-β1 pathway

SIRT2 Alleviated Renal Fibrosis by Deacetylating Conserved Lysine 451 on SMAD2 in Renal Tubular Epithelial Cells

Resveratrol Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis Through C3aR/C5aR- Sphingosine Kinase 1 Pathway

A short treatment with resveratrol after a renal ischaemia–reperfusion injury prevents maladaptive repair and long‐term chronic kidney disease in rats

Extracellular vesicles produced by bone marrow mesenchymal stem cells attenuate renal fibrosis, in part by inhibiting the RhoA/ROCK pathway, in a UUO rat model

Effect of transforming growth flactor-beta 1 on stromal cell-derived factor 1 expression in rat renal tubular epithelial cells

Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury